-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Ds1c0wZk5vEZQCrzfal7kK1q/rL73nfhFk3IdHhS3CI/szphID6D3NrRQ+brwrY6
 oMgitKowoz1lupypvLInYA==

<SEC-DOCUMENT>0001144204-06-010649.txt : 20060320
<SEC-HEADER>0001144204-06-010649.hdr.sgml : 20060320
<ACCEPTANCE-DATETIME>20060320081659
ACCESSION NUMBER:		0001144204-06-010649
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20060320
FILED AS OF DATE:		20060320
DATE AS OF CHANGE:		20060320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			pSivida LTD
		CENTRAL INDEX KEY:			0001314102
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51122
		FILM NUMBER:		06697451

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12 BGC CENTRE
		STREET 2:		28 THE ESPLANADE
		CITY:			PERTH
		STATE:			C3
		ZIP:			6000
		BUSINESS PHONE:		61 8 9226 5099

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12 BGC CENTRE
		STREET 2:		28 THE ESPLANADE
		CITY:			PERTH
		STATE:			C3
		ZIP:			6000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v038147_6k.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARIZER HTML 3.0.2.1 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION<br></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>FORM
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
      OF
      FOREIGN ISSUER<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to Rule 13a-16 or 15d-16 of<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Securities Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      month of March 2006<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number 000-5112</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></strong></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>pSivida
      Limited<br></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant&#8217;s name into English) </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
      12
      BGC Centre<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
      The
      Esplanade<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
      WA
      6000<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form&#160;20-F or Form&#160;40-F). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
      40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant by furnishing the information contained
      in
      this Form is also thereby furnishing the information to the Commission pursuant
      to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      "Yes"
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant,
      pSivida Limited, has duly caused this report to be signed on its behalf by
      the
      undersigned, thereunto duly authorized. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:
              March 20,
              2006</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">pSivida
              Limited</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td>&#160;</td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/&#160;Aaron
              Finlay</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%">
            </td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Aaron
                Finlay</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chief
                Financial Officer and Company
                Secretary</em></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 207pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 207pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 207pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
      INDEX</u></em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                99.1:</strong></font></div>
            </td>
            <td align="left" valign="top" width="62%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                Manufacture Certified to be GMP Equivalent to EU
                Standards</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v038147_ex99-1.htm
<TEXT>
<html>
  <head>
    <title></title>
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div align="center">
        <table bgcolor="white" border="0" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="white">
              <td width="50%">&#160;</td>
              <td width="50%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&nbsp;<IMG SRC="logo.jpg">&nbsp;</div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td width="50%">&#160;</td>
              <td width="50%">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td width="50%"><strong><font size="2">ASX/MEDIA RELEASE</font></strong></td>
              <td width="50%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><strong><font size="2">20
                  March
                  2006</font></strong></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;&#160;&#160;&#160;&#160;&#160;&#160;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font>
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      </strong></font></div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 20pt; FONT-FAMILY: Arial, sans-serif"><strong>Medidur</strong></font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><sup><strong>TM</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 20pt; FONT-FAMILY: Arial, sans-serif"><strong>
      Manufacture Certified to be GMP <br>Equivalent to EU
      Standards</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <hr style="COLOR: black" align="left" noshade size="2" width="100%">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Global
      bio-nanotech company pSivida Limited </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(NASDAQ:PSDV,
      ASX:PSD, Xetra:PSI)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      today
      announced that following an independent audit of its Boston, Massachusetts
      facility by a European Qualified Person (QP), the QP issued a certificate that
      Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is
      manufactured to a standard of GMP (Good Manufacturing Practice) equivalent
      to
      that in the European Union, as set out in directive 2003/94/EC and the EC Guide
      to Good Manufacturing Practice.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div align="center">
      <table bgcolor="white" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="white">
            <td valign="top" width="80%"><font size="2">Medidur<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>&#8482;</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
              is
              a tiny, injectable device designed for the sustained release of the
              drug
              </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">fluocinolone
              acetonide and is being studied for the treatment of Diabetic Macular
              Edema
              (DME), the leading cause of blindness for Americans under the age of
              65.
              Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
              is
              in Phase III clinical trials in DME </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">in
              collaboration with Alimera Sciences Inc.,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
              a
              specialty pharmaceutical company focused on the ophthalmic
              industry.</font></font></td>
            <td width="5%">&#160;</td>
            <td valign="top" width="15%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&nbsp;<IMG SRC="finger.jpg">&nbsp;</div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td width="80%">&#160;</td>
            <td width="5%">&#160;</td>
            <td width="15%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><em><font size="2">Injectable
                Medidur</font></em></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>-ENDS-</strong></font></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="justify" valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                Limited</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                Leedman</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                Relations</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                + 61 8 9226 5099</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
            </td>
            <td align="justify" valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                Public Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
                Jedynak</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                E. Janis &amp; Company, Inc</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +1 (312) 943 1100 ext. 12</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
            </td>
            <td align="justify" valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UK
                &amp; Europe Public</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                Swallow / Helena Podd</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Citigate
                Dewe Rogerson</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +44 (0)20 7638 9571</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">mark.swallow@citigatedr.co.uk</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
      TO EDITORS: </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is a global bio-nanotech company committed to the biomedical sector and the
      development of drug delivery products. Retisert&#8482; is FDA approved for the
      treatment of uveitis. Vitrasert&#174; is FDA approved for the treatment of
      AIDS-related CMV Retinitis. The technologies underlying both of these products
      are licensed to Bausch &amp; Lomb.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      owns the rights to develop and commercialise a modified form of silicon
      (porosified or nano-structrured silicon) known as BioSilicon&#8482;, which has
      applications in drug delivery, wound healing, orthopaedics, and tissue
      engineering. pSivida&#8217;s subsidiary, AION Diagnostics Limited is developing
      diagnostic products and the subsidiary pSiNutria is developing food technology
      products both using BioSilicon&#8482;. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
      intellectual property portfolio consists of 70 patent families, 74 granted
      patents and over 290 patent applications.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      conducts its operations from offices and facilities near Boston in
      Massachusetts, Malvern in the United Kingdom, Perth in Western Australia and
      Singapore. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
      the
      Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
      and in
      Germany on the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Symbol:
      PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
      pSivida is a founding member of the NASDAQ Health Care Index and the Merrill
      Lynch Nanotechnology Index.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company's largest shareholder and a strategic partner is QinetiQ, a leading
      international defence, security and technology company, formed in July 2001
      from
      the UK Government's Defence Evaluation &amp; Research Agency
      (DERA).&#160;QinetiQ was instrumental in discovering BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>(TM)</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
      pSivida enjoys a strong relationship with it having access to its cutting edge
      research and development facilities. For more information visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.QinetiQ.com</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      more
      information, visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.psivida.com</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      document contains forward-looking statements that involve risks and
      uncertainties.&#160; The statements are indicated by the use of words such as
      "believes", "expects", "anticipates" and similar words and phrases.&#160;
Although we believe that the expectations reflected in such forward-looking
      statements are reasonable at this time, we can give no assurance that such
      expectations will prove to be correct. Given these uncertainties, readers are
      cautioned not to place undue reliance on such forward-looking statements. Actual
      results could differ materially from those anticipated in these forward-looking
      statements due to many important factors including: our failure to develop
      applications for BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      due to
      regulatory, scientific or other issues, our inability to successfully integrate
      the operations and employees related to our December 2005 acquisition of Control
      Delivery Systems (CDS); the failure of the CDS&#8217; products to achieve expected
      revenues and the combined entity&#8217;s inability to develop existing or proposed
      products; the failure of the Bausch &amp; Lomb/ Novartis co-promotion
      arrangement to provide faster royalty growth; failure to continue to manufacture
      Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      to the
      European Union standard of GMP; inability to manufacture Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      to the
      United States standard of GMP. Other reasons are contained in cautionary
      statements in the Registration Statement on Form 20-F filed with the U.S.
      Securities and Exchange Commission, including, without limitation, under Item
      3.D, "Risk Factors" therein. We do not undertake to update any oral or written
      forward-looking statements that may be made by or on behalf of
      pSivida.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>finger.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 finger.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0`617AI9@``24DJ``@```````````#_
MVP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+#!D2$P\4'1H?'AT:'!P@)"XG("(L
M(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_VP!#`0D)"0P+#!@-#1@R(1PA,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C+_P``1"`"(`*8#`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"
M`P0%!@<("0H+_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A
M!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9
MFJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?H
MZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+
M_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1
MH;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G
MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W
M^/GZ_]H`#`,!``(1`Q$`/P#PBEI!2U(!1110`4448H`**6B@8E+11BD`44N*
M*`$HI<4X*3T&?I0`RBIUM+AONP2G_@!H:UG0?-#(/JIHNBK,AI*7'-%,D2BE
MHH`2BEHH$-HHHH`****`"EHQ5BULKB]D\NWB9V]NGYTF[#2N048KKK#X>ZK>
M8,K1PIZYR:ZJQ^&FG0A6N99)V'7G`K&5>$>IT0PM270\JBB>:01QJ68]`!6A
M!X?U:X;$=C,><<KC^=>V67AW3[,#R+=5QT)-:L-LB\`8^E8RQ?9'3'`_S,\;
MLOAUK-SS*$A7WYKHK'X90)M-S+YC=^N/YUZ:L(*;5'UIXMBO4=16,L149O#"
MTENCCK7P+I-OC%K&3W.VM2+PSIR#BTB_*M]45>JU*L:Y!/ZUDYR>[.A0A'9&
M(NBVJ\"W0?\``:270;.1<-!&?PK<?:@XR:@9U.00,U-V7:Z.&U?P)8W<;&.)
M%?'!QBO,]=\,WFC299"T1_B`Z5[Y(P_.LC5=/BU"W:-USP<5O3KRB]=CFK86
M-1::,^?J2MWQ'H3:1>-C_5,>/:L.O1C)25T>/.+@[,2BEHJB!E%%36UK-=S"
M*",NY["D-*Y#6AIND7FJS".VB)_VB#BNMT3P1ETDOAN/4KG@5Z!96$%G&J0Q
MJ@'H*YJF(2TB=E+"2EK+0Y#1_AS;1A9-1D,S]=@X%=I8Z5:6:*EO!&BCT6K2
MXS@5813QQQ7'.I*>[/2IT806B$6/.`!4ZQ9Z<@4Y1A>@S]:<!NP!@G'/(_KT
M'>LS:Z%A3<?E!;Z=/TS5D(L9"E0VX<`$#GZ=?QQ3(%#L?E5\_=.TM_7KZ"K2
MJF_8O[I#@_+\I<_J>_8=CTZ4[&<I*X*H1P.`6)QP>/PZ_G2[05VGIGO[4TQ!
M3(O(3;G!X);&1NY_F146_<!N()Y!;KGV'M[#\Z!;[#\`$X!"XR/84PN!STX[
MTSS,@DG)Q]X$'_ZW7_/0U#(V#P:0T$LQ!QBH3)D>]#/^?O43'`H+OH([X%0%
M_P`137DQG)J`2#GFF,P?%.G1W]A("OS`9%>/RQF*5HVZJ<5[??L&!7L1@UY!
MKT0BU64`8!.:[<++>)Y>.AM(S****[#SC7TCPU?:JX*H8XN[L*]'T;P[;Z3"
M%1=SXY8@5J6EM!;1!(D"J/0589OE./2O.J5I3TZ'K4*$8:]0B`5>E6!)D8`J
MI&^<#M4@<`\]JQL=D6B["<]#S5I'!(4''7D]JSHY?F`]34XE(C;Y@,GDX]C0
M4RWNW$CMS4\;8*@.P`(8;1T.>">@]/SJFL@6/WSP?7C]/_K]:DBFVDXR/D)!
M0[3C'//H1_.D)F@MQ'+Y99CAF!)SZ`],MT[9X_I4PF@CXWL$E/WHW!D!'/55
M[Y&<'H/RH"6->5>9L_/&T9(.[J#CZ\Y&1[]*1&0321W$H9V+2L'Y(90`Q)#9
M;(P<\8\H\<\S.7(KF+1>EE`AC#GRGMP-L.W`)X.2/NKUZGN>AJ"5OW@W#`X7
MH?NCIUYQCVP>,*:?--$%WQ/A5RHY.!TP<Y)QT&,K_2J,CD@A4V[`01@<8!./
MIQG`^N#UJF5!6)Y9#&.1R<L#_GZ?SZ\U"7))]CT_S_G'TJJ[8#*2Q8_>.<EC
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M`#^%.$Q8#.<9XXHL.QJK.I(QA5SG!&>_IW)QV_.DN9I$S-%F6:W*N(]Q8%1Q
MC`&=N#M.3T8C!R*S/-XQD8QSSP0.WTJ03X'!4E<@!ESD')P!T'?\:3BI*S$T
M:<]W']H)@R\!),;L&W./7YN>1CM5?S@R\[E`^48;H/3_`#P<=JSUNEVC:1Y:
M\;0@3\\5$;A6)Q_/%"C96&D7VDX&T@-Z9Y'^>3_^JH)).#@G!Z?G@?I5(W/&
M">.G`^E,>X4;1WP/S!I\HKEQY,1Y'N>/TJM+.>>?2F-.,)SQC%4Y)>>#C%-(
MBY9#')YXS399MN>>HXJMYV!]!ZU4NKD*O)Q5*-R7(KZG>!(G.1TK@+F0RW#N
M?6MK6;\2#8AK`KMHPLCS,34YG8****W.0]8#8-3*_KTJMQG.:D5@/K7F'N7&
MYV$CW(HD?Y,^G(]*9/*N]0.XIGFE1P1Z&G8I2+<<J\#.!_>S^E2B0%2PQUX/
MXUEQOM8J1P.GM4_FX7!'S=P#_.DT7S%UI&=ARV?3/7BI@YZ8^;/IBJ*.`"#C
M_P"M3UE`[8-*P^8LF8*2?SYQBD-T!M)`)'/_`.OUJG+(#D@@'K4'FYR<T6!M
M%M[G<?O?D,8_`5&9@1UZ]/>J33$<@TP/SG.!VQ5)$N=B^92".>>M1>;P1P03
MT[K5-YP?XA[?Y_SWJO\`:OF.#^M-1(YS0ENOX1SU]J@,IY)ZFJ1N`#FH;B^"
M+P?UJE$RE4-"6[6->37/ZGJ>1@']:JW6HN^?FK*EE,C9)K:%/JSEJUK(:[EV
M)-,I:*Z4<38E%+10(]*60CJ:3S3G&:@WX)IIE&>*\^Q["9,[9&._:H_-WJ1N
MP/>F[\]:K.^R7ZT[%<Q9$WW>>`>N>E.\_'OSP,?SK.:?:YYZ\BA[C(^E.P*1
MIFYYSN_#CBD%V`>HS65Y^#R34;7('4TN0?.;#76<Y8D]^?UJ,W!()!X]!6,U
MWV!.*079(QN-5R$NH:S7(XR1CUI#<X!VGDC%9)G]343WN!@'GO5*!E*H:,D_
M'WOQS58W('&<8ZU0>ZXZU5DN,]":M0,W5+LU\>@-49+DMDEJKL_O3"2>36B@
MCGG5%9RW>FT459@W<****8@HH-%`'?'\ZA9ST-,:7WJ"24<UPI'J<Q(TV#44
M\P92M5Y)<=*@:6K41<PLDQZ]Z9]IQ4$KYS4&XXS5\IFYEIKC.>3433U`3Q3"
M_O5*(G,F,W-'GD=ZJEJ3<:?*9N98:X)[U"9"33#[TTGGBJ42'4'E_6FEO2FT
MM58S<FQ**6B@D2BEHIB$I:**`$HI:*`.A>X/K4+3D]Z**YK'<VR%I3W-1L^>
M]%%78FY$S5$7Q115$7&EZ;G-%%58AL3(%-+'M113(DQ.]%%%!`4M%%`!1115
16`****+`%%%%%@"BBBD!_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``\`,8#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBHYYA!
M`\I1W"C.U!DGZ"E*2BG)[("2BJ5KJEO=3>2!)%-C(CE7:2/:G76IV=E(L=Q-
ML9AD#:3Q^`K!8J@Z?M.=<O>X^5WL6Z*S?[?TS_GY_P#(;?X5CW]IJOBBX:*V
MUA++1`=LGV16%Q*>#M+L!L'/8'\<\%+%X>K+EIU$WY-,F?-%7L3:KXPM;2^.
MF:7;2ZOJW>UM2,1^\CGY8Q]>>1Q55].\97\)GN_$-GI!`)$%G:"54'4;GD/)
M]<`"KVF_V)X>MC8:18L(D/SBVC+9;_:8\L?<DU#XH>ZU8CPSIKM'-=(&O;@#
MBVMB<'_@;X*J/9CQBM*6(I56U3=[;F4X22O/[EI_P1_@76+[7O!]CJ.HJHN9
M0P+*,;PK%0V.V<?3N,`XKHZAL[2"PLH+.VC$<$$:QQH/X5`P!4U:,T@FHI/<
M****"@HJNU_9HQ5KN!6'4&0`BIU8,H92"#T(/6HC4A)VBTPL+15>[OK:Q"FX
MDV!\[?E)S^52Q2I-$DL9RC@,IQC(I*K!S=-27,MU?7[AV>X^BBBM!!16%J7C
M+0-(U5-,OK_RKQ]NV/R9&SN.!R%(_6MV@E2BVTGL%%!(`))P!5*TU?3-0E,5
MEJ-I<R!=Q2&=7('K@'IR/SH&VEH7:***!A1110`4444`<EJ\;07!N$4HR395
MA%(.^1R3C\JWK^_M(;)!/-'&UT/+A1CS(Q7.`.]9FMV<CO*(H&<MAP4@)^N6
MW?7M5"QT.UO=0FUZZNFNKF&W$5K;N,+:80!B!ZL03GWQ7SN$7L<57I25E)77
MG:YI4<G%.)2L`#J%J",@S)D'ZBNPUB=K?2;AU.&V[01[G']:X_3_`/D)6G_7
M9/\`T(5T?B&=7MELHOWD\CCY%Y(`YKS,HJ^RR^O*]GLO5K0UJ*\T0Z!;%"C[
M,$QE@QBD')]R=IX]*V;2SBLUDV#+RN9)9&^](QXR3]``/0``<`51T>W,>6:+
M850)EH2A/_CQST]!6M7TF54O986,;6,*FLKA7/V7C?PUJ`N#;:M"5MX_-E9P
MR!%R!DE@!U('XUT%?/'PTT*Q\0^*)+/4D>2U2V:<Q*Y4.P90-V.2!N)^H'TK
MTTDTVSCKUIPG"$5O<]HTCQKX=UV]^Q:=J<<MS@D1LCH6QUV[@-W'/&>*F\1W
M4D%@L<;%3*VUB/3'(_E7B_BC3K;PE\3+8:8IB@CE@N(X\D[.1D9)R0<'\\5[
MIJFGKJ-H8MVUU.Y&]#_A7'F5*I4PLX4?B:T+PE>4Y-5%K%F!I^@"]T\7'G[&
M?.Q=O`P<<_E5KP_%?VUP\4L$BVYSG=P%8=QG^E9T<^HZ%/L92JDYV-RC>X/^
M%=)INJPZE&=HV2K]Z,G]1ZBOFLJIX256FE>G5ANOYOO_`"T_4[YN5GU1'J\>
MGR+#]OD9`"=F,\^O04MSJ>FZ)HB7MS<>581J@\TJS8!("YP,]2*H>*O]7:_[
MS?TI=3TS^V?`D^GA=SS66(Q_MA<K_P"/`5[.'K*695:?*E9+7J]MS&I=4KQW
M-'2-:T[7K,W>F7*W$"N8RZJ1A@`2.0/453@\7:#<ZV=&AU!'U`2/$80C9W+D
ML,XQQ@]^U><?!_6X[+3]>@N&(B@C%Z![!2'/Y*E5O@_9OJ7BK4M9N`&>&(DD
M_P#/25B<C\%8?C7LN-KGGPQ4IJG9:RW^1U7BBR\$3>+X9=9OYHM5'E;(U+8.
M#\G12.OO7?2RQP0O--(L<4:EG=SA5`Y))/05X?\`$?\`Y*G:_P#;M_Z%7=_%
MF[DM?`DT<9(^T31PL0<?+G<?SVX_&AK8(5E%U96V_$T[3QSX:U>:2QLM6BDN
M64A4963>?12P`8^PS7E_P6_Y&^Y_[!S_`/HR.M7P%X&T/7/!,U]J-L\ES+)(
M$E61E:,+P-N#CJ">0??(K+^"YSXPNC_U#W_]&1T[))V,'.I.I2E-+7L>RZKK
M6FZ';?:-3O8;6(G"F1N6/H!U)^E9.G_$#PMJEVEK:ZO&9G(5%EC>+<3T`+J`
M3[5SOBWX>:IXJ\5K?3ZE`FFIY<:1#=YB1\;\<8W$[N?IGI7"?$72?"NF3V<?
MAVXB:3YTNH8YS,%(Q@DDG!Z@C/IP*2BF;5\16IWE9<J[[OT/H*BL;PE=2WOA
M#1[B=B\KVD9=F.2QVC)/N>M%0=T7S),V:H:SK%GH.E3ZE?R;+>%<G')8]E`[
MDGBK]<#$C>.?&LDTOS:!H4QCCC)^6XNAU8^H7_#LQ%-$5)N*M'=E_P`-:?JF
ML+<ZUXA:1!?`?9M,WG9;1#E2?]LYY/!YY]!H7/ANT2*26.692JEL9!'3Z5OU
M7OY(X=/N9)9%CC6)BSNP``QU)/2N'&8+#XA.52";M\S2G>FK7.&MHA/=01$D
M"215)'49.*Z>+PU8H09&EE]06P/TYKD-,DGU*YM9;1FM[-I5"7;I\TIR/]4A
MZC_;8;?0-TKT6"!+>((FX^K,Q9F/J2>M>#D>5TW"3Q,$Y7V>Z]5T^>IK.K=^
M[L.CC2&-8XT5$48"J,`4ZBBOJDDE9&05X3\&V5?&MP"P!:PD`!/4[XSQ^1KW
M:OG+X?>'X?$FOW%G+<3VSQVCS03P-AHY`Z`'W^\>/U'6M([,X,6VJU-I=_T-
M7XE$7'Q/BAB8,X%O&0.S$Y`_(C\Z]GU;4WTV.-E@\P.2-Q;`4_E]?RKA/#_P
MG?3_`!%'JNJZK]M,,OG(H0@R.#D,[$D\'G'KW]?1KJUBO+=H9ERC?F#ZBN?&
M1JSHN-"5I6T9KA(2C*4ZBM=[%6UNK;5=-W3",C&)48\*?Z?6N=T3Y==C$3$I
MEQGU7!Z_I5Q_"K[_`)+I2O\`M)S6KIFD0Z;EPQDF88+D8X]`*^=6&QV*KT95
MZ:C[-ZRNM;>AZ%XQ3L]S/\5?ZNU_WF_I6MIG_(*M?^N2_P`JAU;2SJ:Q`3"/
MRR3RN<Y_&K=K#]FM(H"V[RT"YQC.*]&AAJL<QJUFO=DE9_<2VN1(^=M?,_A7
MQ?XBL;<!4N4D@P.`(I2K@#\,"O4_A'I@LO!:W3#Y[Z=Y>G(4?(!_XZ3^--\:
M?#;_`(2S68]1BU);-A`(G4P;]Q!)!SN'8X_`5V6E:>FE:19Z?&VY+:%(@V,;
MMH`SCWZU[,I71Y>'PTH5G)[=/F>,?$?_`)*G:_\`;M_Z%7:_&!&;P0"!D+=Q
MEO888?S(IWB7X=2>(/%D6MKJB0+'Y7[DP;L[#GKN'7Z5UFN:/;:_HMUI=WN\
MFX7!*GE2#D,/<$`_A1S+0:H3?M4_M;'(?"R:-OAT1N4>5+,KG/3^+GTX(KB?
M@M_R-]U_V#G_`/1D==#I7P?FMKIH[[79)=,9@9;:W5H_M`'0-\V!V]3Z$=:V
MO!WP[;PGK]SJ7]I)<)+`\*Q+`4VY=6Z[CTVXIW6I$*59NGS1MRG(^,-9U/Q;
MX\'A.VO&L[`3"W89P'(&69@#\W0X7.#@=":H?$?PKHWA33]*M=.R;J1G::22
M3=(X`&"1T`SGH!76^*?A4^KZ_+J^F:FMI),PD>-T)VN/XE8'(SC./7//85KO
MX-_:K:-GU^:74"Q,US/$7WKC`4#=D8]23^%":5C.I0JSYTXW;V=^GD=IX'_Y
M$;1?^O2/^5%7M!TQM&T&QTUI1,;6%8O,"[=V.^,G%%9L].FFHI,76-7M=$LD
MN[R01PF:.(NWW5W,!DGL!GK69H-OH_A'PW#;G5+7[)ODD6YED5!(&<L"3G!(
M!`SWQVZ5LZCIUIJVGS6%_`L]K,-KQMD9YR.1R#D`Y'3%<O:?"SPC:3>;_9S3
MMG($TS,![8S@CZYIJUC.?/SIQ2([KXB0WMP]CX5T^XUN]'!=%*01GU9SV_0^
MM2V_A+4-59;WQ5?QWER#NAL8T_T2W.>#L_Y:,/5O7O@&NKMK6WLK=8+2WB@A
M7[L<2!5'T`XJ:D[-6&J;>LW?\OZ]3!?P[))<?:'U!S+G=O,?.?SK7M(9H(BL
M]R9V+9#%0N!Z<5/17'A\!0P\G.DFF]]6[_>SH<F]PHHHKL)"N&\'?#A?".M2
M:BNJ-=;[=H/+,&S&65LYW'^[^M=S13N1*G&4E)K5;!1112+"BBB@`HHHH`**
5**`"BBB@`HHHH`****`"BBB@#__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
